OncoMatch/Clinical Trials/NCT06187441
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
Is NCT06187441 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Daratumumab and Dexamethasone for multiple myeloma.
Treatment: Daratumumab · Dexamethasone · Lenalidomide capsule — In the Netherlands, the standard treatment for multiple myeloma is a combination of different medicines named daratumumab-lenalidomide-dexamethasone, abbreviated as Dara-Rd. In many patients this treatment results in suppressing the disease for a long time. The treatment is continued until it is not effective anymore and the disease progresses. But until now it is unknown whether continuous therapy also leads to prolonging life. In addition, there are concerns about side effects, leading to a reduced quality of life, the development of severe toxicity that remains, which hampers subsequent therapy, and high costs due to prolonged treatment. There are indications that temporarily stopping treatment is safe, leading to fewer side effects and allows recovering from toxicity or damage due to treatment. This may improve the quality of life.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: daratumumab, lenalidomide, and dexamethasone (daratumumab, lenalidomide, dexamethasone) — 12 cycles (13 accepted) of Dara-Rd
Patient was treated with 12 cycles (13 cycles is accepted) of Dara-Rd and will continue treatment with Dara-Rd. Reduced dosing of lenalidomide, but not to less than 5 mg, and previous discontinuation or dose reduction of dexamethasone is allowed.
Cannot have received: daratumumab, lenalidomide, or both discontinued (daratumumab, lenalidomide)
Exception: patients may only have discontinued dexamethasone
Patient in whom treatment with daratumumab, lenalidomide or both has been discontinued for whatever reason (patients may only have discontinued dexamethasone).
Lab requirements
Blood counts
anc ≥ 1.0x10^9/l and platelets ≥ 75x10^9/l
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify